RT Journal Article SR Electronic T1 Mutational pressure drives enhanced release of proteasome-generated public CD8+ T cell epitopes from SARS-CoV-2 RBD of Omicron and its current lineages JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.04.03.24305074 DO 10.1101/2024.04.03.24305074 A1 Kudriaeva, Anna A. A1 Butenko, Ivan O. A1 Saratov, George A. A1 Ri, Maxim A1 Mokrushina, Yuliana A. A1 Bondarev, Alexey A. A1 Evpak, Alena S. A1 Smirnov, Ivan V. A1 Matyushkina, Daria S. A1 Gabibov, Alexander G. A1 Govorun, Vadim M. A1 Belogurov, Alexey A. YR 2024 UL http://medrxiv.org/content/early/2024/04/03/2024.04.03.24305074.abstract AB The COVID-19 pandemic was the most dramatic in the newest history with nearly 7 million deaths and global impact on mankind. Here we report binding index of 305 HLA class I molecules from 18,771 unique haplotypes of 28,104 individuals to 821 peptides experimentally observed from spike protein RBD of 5 main SARS-CoV-2 strains hydrolyzed by human proteasomes with constitutive and immune catalytic phenotypes. Our data read that mutations in the hACE2-binding region RBD496-513 of Omicron B.1.1.529 strain results in a dramatic increase of proteasome-mediated release of two public HLA class I epitopes. Global population analysis of HLA class I haplotypes, specific to these peptides, demonstrated decreased mortality of human populations enriched in these haplotypes from COVID-19 after but not before December, 2021, when Omicron became dominant SARS-CoV-2 strain. Noteworthy, currently circulating BA.2.86 and JN.1 lineages contain no amino acid substitutions in RBD496-513 thus preserving identified core epitopes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported, in part, by RSF grants 21-74-10154 (to A.A.K.) (mass spectrometry and bioinformatic studies) and 23-74-00053 (to A.A.B. Jr.) (proteasome samples purification). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Allele Frequency Net Database www.allelefrequencies.net/BrowseGenotype.aspx World Health Organization https://covid19.who.int/WHO-COVID-19-global-data.csvI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesFurther information and requests for resources should be directed to and will be fulfilled by the lead contact, Alexey Belogurov (belogurov{at}ibch.ru). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD050265. The code and pipelines used for data analysis are available upon request. Raw data files are located at Mendeley Data (https://doi.org/10.17632/yc7ht4cgnc.1). https://doi.org/10.17632/yc7ht4cgnc.1 https://www.ebi.ac.uk/pride/archive/projects/PXD050265